.
2020 Virtual Education Programs
In lieu of our Annual Meeting in Hershey, PAAA will be hosting monthly virtual programs throughout the end of the year. Please see below for a list of available programs:
Join us for this upcoming program!
Exploring a Treatment Option for Allergic Asthma
Presented by
Genentech
Presented by
Genentech
Thursday, December 10, 2020 | 7:00 pm
Speaker: Mark Scarupa, MD and Thomas Murphy, MD
Registration coming soon!
Speaker: Mark Scarupa, MD and Thomas Murphy, MD
Registration coming soon!
Past Programs
A Brief Review of Clinical and Real-World Evidence for Using a Biologic to Treat Severe Eosinophilic Asthma
Presented by GSK
Wednesday, November 18, 2020
Diagnosis and Management of Chronic Granulomatous Disease
Presented by Horizon Pharmaceuticals
Wednesday, November 4, 2020
Dupixent® (dupliumab) and the Role of Type 2 Inflammation in Asthma, Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP), and Atopic Dermatitis
Presented by Regeneron
Wednesday, October 21, 2020
A Brief Review of Clinical and Real-World Evidence for Using a Biologic to Treat Severe Eosinophilic Asthma
Presented by GSK
Wednesday, October 7, 2020
A Focus on Type 2 Inflammation in Disease
Presented by Regeneron
Thursday, September 24, 2020
Advancements in Atopic Dermatitis: What Do They Mean For Your Practice?
Presented by The France Foundation
Wednesday, September 2, 2020
Rethinking the Management of Allergic Asthma: A Case-Based Interactive Approach to Diagnosis and Treatment
Presented by Genentech
Thursday, August 20, 2020
Inflammation and Disease Pathophysiology of Chronic Rhinosinusitis with Nasal Polyps (CRS with NP)
Presented by Regeneron
Wednesday, August 12, 2020
Uncontrolled Asthma - Changing the Patient Experience
Presented by GSK
Thursday, July 30, 2020
Type 2 Inflammation in Asthma
Presented by Regeneron
Wednesday, July 22, 2020
Presented by GSK
Wednesday, November 18, 2020
Diagnosis and Management of Chronic Granulomatous Disease
Presented by Horizon Pharmaceuticals
Wednesday, November 4, 2020
Dupixent® (dupliumab) and the Role of Type 2 Inflammation in Asthma, Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP), and Atopic Dermatitis
Presented by Regeneron
Wednesday, October 21, 2020
A Brief Review of Clinical and Real-World Evidence for Using a Biologic to Treat Severe Eosinophilic Asthma
Presented by GSK
Wednesday, October 7, 2020
A Focus on Type 2 Inflammation in Disease
Presented by Regeneron
Thursday, September 24, 2020
Advancements in Atopic Dermatitis: What Do They Mean For Your Practice?
Presented by The France Foundation
Wednesday, September 2, 2020
Rethinking the Management of Allergic Asthma: A Case-Based Interactive Approach to Diagnosis and Treatment
Presented by Genentech
Thursday, August 20, 2020
Inflammation and Disease Pathophysiology of Chronic Rhinosinusitis with Nasal Polyps (CRS with NP)
Presented by Regeneron
Wednesday, August 12, 2020
Uncontrolled Asthma - Changing the Patient Experience
Presented by GSK
Thursday, July 30, 2020
Type 2 Inflammation in Asthma
Presented by Regeneron
Wednesday, July 22, 2020
Questions?
For other questions and more information, please contact the PAAA Meeting Manager, Lauren Newmaster at lnewmaster@pamedsoc.org
or (717) 909-2691.
For other questions and more information, please contact the PAAA Meeting Manager, Lauren Newmaster at lnewmaster@pamedsoc.org
or (717) 909-2691.
